PortfoliosLab logoPortfoliosLab logo
NIC vs. PRLD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NIC vs. PRLD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nicolet Bankshares Inc. (NIC) and Prelude Therapeutics Incorporated (PRLD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NIC achieves a 13.70% return, which is significantly lower than PRLD's 31.38% return.


NIC

1D
0.77%
1M
-6.17%
YTD
13.70%
6M
6.61%
1Y
17.42%
3Y*
25.37%
5Y*
12.71%
10Y*
14.44%

PRLD

1D
-6.62%
1M
-26.02%
YTD
31.38%
6M
160.96%
1Y
269.90%
3Y*
-12.62%
5Y*
-33.80%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

NIC vs. PRLD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
NIC
Nicolet Bankshares Inc.
13.70%16.76%31.91%1.93%-6.95%29.24%21.14%
PRLD
Prelude Therapeutics Incorporated
31.38%127.45%-70.14%-29.30%-51.49%-82.60%173.09%

Correlation

The correlation between NIC and PRLD is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Sep 28, 2020

0.18

The correlation between NIC and PRLD shifts across timeframes, from 0.11 (1 year) to 0.22 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS

NIC:

$11.59

PRLD:

-$1.05

PS Ratio

NIC:

2.72

PRLD:

16.95

Total Revenue (TTM)

NIC:

$579.85M

PRLD:

$16.72M

Gross Profit (TTM)

NIC:

$296.00M

PRLD:

$11.30M

EBITDA (TTM)

NIC:

$151.89M

PRLD:

-$82.17M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Nicolet Bankshares Inc.

Prelude Therapeutics Incorporated

Often compared with NIC:
NIC vs. RTX

Return for Risk

NIC vs. PRLD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NIC
NIC Risk / Return Rank: 6161
Overall Rank
NIC Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
NIC Sortino Ratio Rank: 5858
Sortino Ratio Rank
NIC Omega Ratio Rank: 5656
Omega Ratio Rank
NIC Calmar Ratio Rank: 6464
Calmar Ratio Rank
NIC Martin Ratio Rank: 6464
Martin Ratio Rank

PRLD
PRLD Risk / Return Rank: 8888
Overall Rank
PRLD Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
PRLD Sortino Ratio Rank: 9090
Sortino Ratio Rank
PRLD Omega Ratio Rank: 9191
Omega Ratio Rank
PRLD Calmar Ratio Rank: 8989
Calmar Ratio Rank
PRLD Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NIC vs. PRLD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nicolet Bankshares Inc. (NIC) and Prelude Therapeutics Incorporated (PRLD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NICPRLDDifference
Sharpe ratioReturn per unit of total volatility

-0.83

Sortino ratioReturn per unit of downside risk

-2.11

Omega ratioGain probability vs. loss probability

1.14

1.45

-0.32

Calmar ratioReturn relative to maximum drawdown

1.11

4.16

-3.05

Martin ratioReturn relative to average drawdown

2.47

8.89

-6.42

NIC vs. PRLD - Sharpe Ratio Comparison

The current NIC Sharpe Ratio is 0.63, which is lower than the PRLD Sharpe Ratio of 1.46. The chart below compares the historical Sharpe Ratios of NIC and PRLD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NICPRLDDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.63

1.46

-0.83

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.42

-0.27

+0.69

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.47

Sharpe Ratio (All Time)

Calculated using the full available price history

0.50

-0.24

+0.73

Drawdowns

NIC vs. PRLD - Drawdown Comparison

The maximum NIC drawdown since its inception was -44.31%, smaller than the maximum PRLD drawdown of -99.33%. Use the drawdown chart below to compare losses from any high point for NIC and PRLD.


Loading charts...

Drawdown Indicators


NICPRLDDifference

Max Drawdown

Largest peak-to-trough decline

-44.31%

-99.33%

+55.02%

Max Drawdown (1Y)

Largest decline over 1 year

-17.90%

-70.10%

+52.20%

Max Drawdown (3Y)

Largest decline over 3 years

-21.73%

-90.42%

+68.69%

Max Drawdown (5Y)

Largest decline over 5 years

-44.31%

-98.42%

+54.11%

Max Drawdown (10Y)

Largest decline over 10 years

-44.31%

Current Drawdown

Current decline from peak

-14.53%

-95.84%

+81.31%

Average Drawdown

Average peak-to-trough decline

-11.19%

-85.19%

+74.00%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.00%

32.72%

-24.72%

Volatility

NIC vs. PRLD - Volatility Comparison

The current volatility for Nicolet Bankshares Inc. (NIC) is 8.73%, while Prelude Therapeutics Incorporated (PRLD) has a volatility of 21.84%. This indicates that NIC experiences smaller price fluctuations and is considered to be less risky than PRLD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NICPRLDDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.73%

21.84%

-13.11%

Volatility (6M)

Calculated over the trailing 6-month period

22.82%

87.69%

-64.87%

Volatility (1Y)

Calculated over the trailing 1-year period

31.29%

199.28%

-167.99%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

30.45%

125.36%

-94.91%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

30.96%

122.20%

-91.24%

Dividends

NIC vs. PRLD - Dividend Comparison

NIC's dividend yield for the trailing twelve months is around 0.96%, while PRLD has not paid dividends to shareholders.


PositionTTM202520242023
NIC
Nicolet Bankshares Inc.
0.96%1.02%1.04%0.93%
PRLD
Prelude Therapeutics Incorporated
0.00%0.00%0.00%0.00%

Financials

NIC vs. PRLD - Financials Comparison

This section allows you to compare key financial metrics between Nicolet Bankshares Inc. and Prelude Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M20222023202420252026
158.21M
4.58M
(NIC) Total Revenue
(PRLD) Total Revenue
Values in USD except per share items

Frequently Asked Questions


NIC and PRLD have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PRLD has higher volatility (21.84%) compared to NIC (8.73%). In terms of maximum drawdown, NIC dropped -44.31% vs PRLD's -99.33%.

PRLD currently has the higher Sharpe Ratio (1.46 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NIC and PRLD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer